Financings Roundup
With CDS Drug Back in House, Targacept Prices $75M Offering
About two weeks after AstraZeneca plc passed on an option for TC-5619, Targacept Inc. priced a $75 million public offering to move forward with the alpha7 neuronic nicotinic receptor-targeting drug on its own, with plans to launch a Phase IIb study in cognitive dysfunction in schizophrenia (CDS).